FIELD OF APPLICATION DETAILS
Generic Name
Atosiban
Active Ingredient
Atosiban acetate
Brand Names
Atosiban Sun, Tractocile
Drug Category
Gynecology
Drug Class
Prophylactic, preventive therapy, Palliative treatment, Immunosuppressive therapy, Targeted therapy
Dosage Forms
Injection, Injection, solution, Injection, solution, concentrate, Solution, Solution, concentrate
Route of Administration
Intravenous, Parenteral
FDA Approval Status
Not approved

Atosiban: Overview

Atosiban belongs to the class of organic compounds known as oligopeptides. Chemically, it is a synthetic peptide analog of oxytocin with modifications at several structural positions.

In clinical obstetrics and gynecology, atosiban functions as a targeted tocolytic agent a medication used to halt uterine contractions and delay imminent preterm labor. By blocking the natural hormones that trigger labor (oxytocin and vasopressin), atosiban provides a critical window of time, typically 48 hours. This delay allows healthcare providers to administer essential treatments, such as maternal corticosteroids to accelerate fetal lung maturity, or to safely transfer the mother to a specialized neonatal care facility.

Key Facts Summary:

Atosiban: What Is It & How Does It Work?

Atosiban acts as a highly specific receptor antagonist, interrupting the biochemical pathways that cause the uterine muscles to contract during labor:

  • Oxytocin and Vasopressin Antagonism: Atosiban binds directly to membrane-bound oxytocin and vasopressin (V1a) receptors on the myometrium (uterine muscle).
  • Calcium Pathway Blockade: By blocking these receptors, it prevents oxytocin-stimulated increases in inositol triphosphate (IP3) production. This halts the release of stored calcium from the sarcoplasmic reticulum and prevents the subsequent opening of voltage-gated calcium channels. Without cytosolic calcium, the uterine muscle cannot contract, inducing a state of uterine quiescence.
  • Biased Ligand Activity: Recent pharmacological studies indicate atosiban acts as a biased ligand. While it successfully antagonizes Gq coupling (stopping contractions), it acts as an agonist of Gi coupling. This secondary action produces a mild pro-inflammatory effect in the human amnion (activating NF-κB), which is a key area of ongoing research regarding its overall clinical effectiveness.

Atosiban: FDA Approval & Uses

Understanding the regulatory status of atosiban clarifies its international scope in labor management and tocolysis.

Global Regulatory Status

No. Atosiban is Not Approved by the US Food and Drug Administration (FDA) for use in the United States. However, it is fully approved and widely utilized in the European Union, the United Kingdom, and various other international markets under brand names like Tractocile.

Primary Indications

Where approved internationally, atosiban is specifically indicated for delaying imminent preterm birth in pregnant adult women displaying all of the following clinical observations:

  • Gestational Age: A pregnancy between 24 and 33 completed weeks.
  • Uterine Contractions: Regular uterine contractions lasting at least 30 seconds at a rate of at least 4 per 30 minutes.
  • Cervical Dilation and Effacement: A cervical dilation of 1 to 3 cm (0 to 3 cm for first-time mothers) and an effacement of at least 50%.
  • Fetal Health: A normal fetal heart rate, indicating no immediate fetal distress.

Before Taking Atosiban: Contraindications & Precautions

Before starting treatment with or receiving atosiban, patients must review key safety precautions and underlying health risks with their healthcare provider.

Who Should Not Take Atosiban?

  • Women experiencing premature rupture of membranes (PROM) beyond 30 weeks of gestation.
  • Patients with an abnormal fetal heart rate, severe pre-eclampsia, or eclampsia requiring immediate delivery.
  • Women with intrauterine fetal death, suspected intrauterine infection (chorioamnionitis), or antepartum hemorrhage requiring immediate delivery.
  • Patients with a gestational age outside the 24 to 33-week window.

Atosiban: Pregnancy & Breastfeeding

Atosiban is exclusively indicated for use during a specific stage of pregnancy to delay labor. Once the clinical window for delaying labor has passed or if the baby is delivered, the medication is discontinued. In clinical trials, small amounts of atosiban were found to pass into breast milk; however, because the drug is discontinued before full-term nursing begins, breastfeeding is considered safe.

Tell Your Doctor Before Taking Atosiban

Because this medication is administered in emergency obstetric settings, doctors will rapidly assess maternal and fetal health. Patients must inform the medical team of any known allergies to peptides, underlying kidney or liver dysfunction, or recent episodes of vaginal bleeding.

Atosiban: Dosage & Administration

Because atosiban is used for continuous tocolytic therapy, administration follows a strict three-stage parenteral infusion protocol.

Standard Atosiban Dosing

  • Initial Bolus: An initial intravenous bolus dose is administered over 1 minute.
  • High-Dose Infusion: Followed immediately by a continuous high-dose intravenous infusion for 3 hours.
  • Maintenance Infusion: Followed by a lower-dose maintenance infusion for up to 45 hours. The total duration of treatment does not typically exceed 48 hours.

How Atosiban Is Administered

  • Dosage Forms: Supplied as sterile Injection solutions and concentrates for infusion.
  • Administration Routes: Administered exclusively via the Intravenous (Parenteral) route by a qualified healthcare professional in a hospital setting.

Atosiban: Clinical Efficacy & Research

Clinical trials and international obstetric studies establish the tocolytic efficacy of oxytocin receptor antagonists. Research highlights its capacity to achieve 48-hour labor suppression with significantly fewer maternal cardiovascular side effects than non-specific uterine relaxants.

Trial Findings and Efficacy

Extensive clinical trials in Europe have demonstrated that atosiban is highly effective at delaying preterm birth for up to 48 hours. Its primary clinical advantage over older tocolytic agents (such as beta-agonists like terbutaline or calcium channel blockers) is its targeted, uterus-specific mechanism. Because it does not significantly affect systemic cardiovascular receptors, it is associated with a much lower rate of maternal cardiovascular side effects, such as tachycardia, palpitations, and chest pain, making it a safer profile for the mother.

Atosiban: Side Effects & Safety Profile

BLACK BOX WARNING

As an unapproved drug in the United States, atosiban does not carry an FDA Black Box Warning. In international regulatory frameworks, it is considered a safe tocolytic option. The primary safety concerns surround ensuring that the medication is not used in conditions where delaying labor poses a direct threat to the mother or fetus (such as severe infection or placental abruption).

Understanding the side effect profile of atosiban helps clinical teams and patients monitor for adverse reactions. The side effect profile of atosiban is generally considered favorable compared to other classes of labor-delaying drugs due to its specific targeting of oxytocin receptors.

Common Atosiban Side Effects

  • Nausea and vomiting (the most frequently reported side effects).
  • Headache and mild dizziness.
  • Injection site reactions, including pain, swelling, and redness.
  • Hot flashes or mild tachycardia (though significantly less than beta-agonists).

Serious Atosiban Adverse Events

  • Postpartum Hemorrhage: Because it relaxes the uterus, there is a theoretical risk of increased uterine relaxation after delivery, potentially leading to heavier bleeding.
  • Hypersensitivity Reactions: Rare instances of severe allergic reactions or anaphylaxis to the peptide formulation.

Managing Atosiban Side Effects

Administration occurs strictly within a hospital maternity ward. Maternal blood pressure, heart rate, and uterine contractions, along with continuous fetal heart rate monitoring, are conducted throughout the infusion. If signs of fetal distress or severe maternal allergic reaction occur, the infusion is stopped immediately and emergency delivery protocols are initiated.

Atosiban: Drug Interactions & What to Avoid

Atosiban exhibits minimal systemic drug interactions, though co-administration with other tocolytics requires caution.

Key Atosiban Interactions

  • Other Tocolytic Agents: Co-administration with other labor-delaying drugs (such as beta-mimetics or calcium channel blockers) is generally not recommended, as it can cause unpredictable cardiovascular or uterine responses.
  • Labetalol: In vitro studies have shown no significant interactions with labetalol, a drug frequently used to manage pregnancy-induced hypertension.

Atosiban: Food & Alcohol

Because the drug is administered intravenously in an acute hospital setting during imminent preterm labor, food and alcohol interactions are not clinically applicable.

Atosiban: Missed Dose, Overdose & Storage

Proper facility handling, refrigeration, and pump administration protocols govern parenteral oligopeptide management.

Missed Dose of Atosiban

Since the medication is administered as a continuous intravenous infusion by hospital staff using a controlled infusion pump, a missed dose is not applicable.

Atosiban: Overdose

An overdose is highly unlikely due to strict hospital controls. If an overdose were to occur, it would likely result in exaggerated pharmacological effects, such as excessive uterine relaxation or gastrointestinal distress. There is no specific antidote; management requires stopping the infusion and providing supportive clinical care.

How to Store Atosiban

Vials of the injection solution are stored in hospital pharmacies at controlled refrigerated temperatures (2°C to 8°C). Once diluted for infusion, the solution must be used within 24 hours.

Atosiban: Patient Management & Guidelines

Effective clinical management relies on continuous cardiotocography (CTG) and strict monitoring of cervical dilation limits.

Tests Before & During Atosiban Treatment

  • Cardiotocography (CTG): Continuous electronic monitoring of the fetal heart rate and maternal uterine contractions is mandatory before and during the infusion.
  • Cervical Examinations: Clinical assessment of cervical dilation and effacement to confirm the patient is within the strict 1-3 cm treatment window.
  • Ultrasound: To accurately confirm gestational age, fetal position, and amniotic fluid levels.

Atosiban: Do’s and Don’ts

  • Do immediately inform the nursing staff if you experience shortness of breath, chest pain, or severe nausea during the infusion.
  • Do remain in bed and rest comfortably while the clinical team monitors the medication’s effect on your contractions.
  • Do not attempt to adjust the intravenous lines or infusion pumps delivering the medication.

Frequently Asked Questions

What is Atosiban used for?

It is a medication given through an IV to pregnant women to stop early (premature) labor contractions. It buys critical time, usually 48 hours, so doctors can give the mother steroids to help the baby’s lungs develop before birth.

Is Atosiban approved by the FDA?

No, it is not approved for use in the United States. However, it is an approved and commonly used medication in Europe, the UK, and several other countries.

How does Atosiban stop labor?

It blocks the effects of oxytocin, which is the main hormone in the body that signals the uterine muscles to squeeze and contract during labor.

Why is it only used between 24 and 33 weeks of pregnancy?

Before 24 weeks, the baby is generally considered too underdeveloped for tocolytic interventions to be standard practice. After 33 to 34 weeks, the baby’s lungs are usually mature enough that delaying labor is no longer necessary, and the risks of delaying birth outweigh the benefits.

Is Atosiban safer than other drugs used to stop labor?

In many international guidelines, it is considered safer for the mother than older drugs (like terbutaline) because it specifically targets the uterus and does not cause severe rapid heart rate, palpitations, or chest pain.

Will it harm my baby?

Clinical trials have shown that when used within the appropriate gestational window, atosiban does not cause adverse effects on the fetus.

References

  • DrugBank Database – Atosiban Clinical and Pharmacological Profile
  • European Medicines Agency (EMA) Prescribing Information for Tractocile
  • International Guidelines on the Management of Preterm Labor and Tocolysis

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider regarding medical conditions or treatment plans.